Advertisement
Organisation › Details
Immunic (Group)
https://www.immunic-therapeutics.com
LinkedIn: https://www.linkedin.com/company/immunic-therapeutics
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR?/ROR?t, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. *
Start | 2019-04-12 renamed | |
Industry | immuno modulatory compound (IMO) | |
Industry 2 | MS DRUGS | |
Person | Vitt, Daniel (Immunic 201701– CEO before 4SC 1997–201612 CSO + Co-Founder before Univ Würzburg) | |
Person 2 | Whaley, Glenn (Immunic 202203– promoted to CFO joined 2019 before Pernix Therapeutics + Alvogen) | |
Region | Gräfelfing | |
Country | Germany | |
Street | 21 Lochhamer Schlag | |
City | 82166 Gräfelfing | |
Tel | +49-89-250079460 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | C: 51 to 100 (2023-01-01) |
Currency | USD | |
Profit | -120,407,000 (2022-12-31) | |
Cash | 106,745,000 (2022-12-31) | |
* Document for »About Section«: Immunic, Inc.. (3/16/22). "Press Release: Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer". New York, NY. | ||
Record changed: 2023-12-30 |
Advertisement
More documents for Immunic (Group)
- [1] Immunic, Inc.. (1/5/24). "Press Release: Immunic, Inc. Announces Private Placement of up to $240 Million". New York, NY....
- [2] Immunic, Inc.. (11/2/23). "Press Release: Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts". New York, NY....
- [3] Immunic, Inc.. (10/10/22). "Press Release: Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing". New York, NY....
- [4] Immunic, Inc.. (7/6/22). "Press Release: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén". New York, NY....
- [5] Immunic, Inc.. (6/2/22). "Press Release: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update". New York, NY....
- [6] Immunic, Inc.. (3/16/22). "Press Release: Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer". New York, NY....
- [7] Immunic, Inc.. (10/14/21). "Press Release: Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer". New York, NY....
- [8] Immunic, Inc.. (7/19/21). "Press Release: Immunic, Inc. Announces Closing of $45.0 Million Public Offering". New York, NY....
- [9] Immunic, Inc.. (3/31/21). "Press Release: Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838". New York, NY & Planegg-Martinsried....
- [10] Immunic, Inc.. (2/26/21). "Press Release: Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity". New York, NY....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top